Bilcare share price
NSE: BIBSE: 526853Healthcare ServicesSmall Cap
Bilcare Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995
Last close ₹81.44down ₹1.18 (1.43%)BSE ₹81.12
Share price at the NSE close on 28 Oct 2026. Previous close ₹82.62.
28 Oct: open ₹83.03, high ₹84.19, low ₹81.00
52-week range of BSE trades to 28 Oct 2026
₹50.00Low, 27 Mar 2026₹114.55High, 21 Sep 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Next results date: the board meets on 3 Nov 2026 to consider: quarterly results. Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹192 Cr2,627th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.97
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 5.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 8.37
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 4,397
Results
Consolidated; ₹ crore.Bilcare quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −0.9%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹226 Crup 20.36%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹15 Crup 90.70%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 6.6%
Revenue by quarter
Peak revenue ₹226 Cr, quarter to Jun 2026; lowest ₹178 Cr, quarter to Sep 2025
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 5 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 202 | 198 | 194 | 186 | 178 | 181 | 188 | 226 |
| Net profit | −30 | −16 | 5 | −10 | −23 | −13 | 8 | 15 |
| Net margin | −14.8% | −8.2% | 2.6% | −5.2% | −13.1% | −7.1% | 4.2% | 6.6% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹734 Crdown 6.92%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹17 CrYear to Mar 2025: −₹56 Cr
- Net margin
- −2.4%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 9 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2018, GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty. From the year to Mar 2020, the company's revenue for that year, ₹507 Cr, differs from its quarters added, ₹1,626 Cr; the company reports a discontinued business.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,680what Revenue, Mar 2017, includes. This period's revenue includes excise duty of ₹47 crore, a tax on the goods the company makes that it collects and pays to the government. | 2,790what Revenue, Mar 2018, includes. This period's revenue includes excise duty of ₹12 crore, a tax on the goods the company makes that it collects and pays to the government. | 2,997 | 507 | 623 | 845 | 982 | 747 | 788 | 734 |
| Net profit | −82 | −199 | −453 | −99 | −11 | −4 | 50 | −59 | −56 | −17 |
| Net margin | −3.0% | −7.1% | −15.1% | – | −1.8% | −0.5% | 5.1% | −7.8% | −7.1% | −2.4% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share. Net margin is left blank for Mar 2020: the profit includes the result of a business the company has discontinued, which the revenue does not, so the two make no margin.
Business segments
In the year to Mar 2026 the company reports one business segment, The Company's main business segment is pharma packaging research solutions, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: a results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement. Dividend yield is not shown: no dividend in the years on record.Bilcare PE ratio and valuation
Price to book
At or below today's level on 64% of 1,218 trading days over the last 5 years.
LowestHighest
Its median0.42Industry median2.85
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −42.7% | – | – | 0.0% |
| 3 years | +6.7% | −51.5% | +119.9% | 0.0% |
| 5 years | −1.8% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 3 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2023 and Mar 2026.
Bilcare competitors and peers
Healthcare Research, Analytics & Technology, 11 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Bilcare in market cap.Healthcare companies
Bilcare is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Syngene InternationalSYNGENE | 16,585 | 89.12 | 3.41 | −6.0% | −60.3% | 3.9% | 6.1% | 0.30% |
 IndegeneINDGN | 14,433 | 36.00 | 4.60 | +30.4% | −7.9% | 13.9% | 15.6% | 0.38% |
 Suven Life SciencesSUVEN | 7,574 | – | – | +17.3% | – | −100.5% | −63.0% | 0.00% |
 Vimta LabsVIMTALABS | 2,295 | 28.81 | 5.02 | +15.2% | – | 19.1% | 21.4% | 0.39% |
 Novelix PharmaceuticalsNOVELIX | 175 | 48.19 | – | +179.9% | – | 11.3% | 8.7% | 0.00% |
 Jeevan Scientific TechnologyJSTL | 164 | – | 2.28 | +66.1% | – | – | 8.8% | 0.00% |
 TAKETAKE | 156 | 12.16 | 5.03 | – | −68.2% | 49.8% | −5.6% | 0.00% |
 GlobalSpace Technologies540654 | 82 | – | 1.44 | +37.2% | – | – | 7.5% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Bilcare dividend history
| Ex-date | Type | Per share |
|---|---|---|
| 20 Sep 2012 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹2.00 |
| 20 Sep 2011 | Final | ₹3.00 |
| 23 Sep 2010 | Final | ₹2.50 |
| 17 Sep 2009 | Final | ₹2.50 |
| 20 Sep 2007 | Final | ₹4.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Bilcare announcements
Oct 2026
27 Oct · Board meeting
Meeting on 3 Nov 2026: quarterly results19 Oct · Announcement Under Regulation 30(LODR) - Update On Voluntary Winding Up Of Bilcare INC US
15 Oct · Management
Sep 2026
Bilcare share price by year
Each calendar year to 2025.Bilcare share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025BSE close | 79.67 | +21.5% | 112.45 | 52.62 |
| 2024BSE close | 65.57 | −17.0% | 91.19 | 53.34 |
| 2023BSE close | 79.03 | +108.0% | 93.95 | 39.90 |
| 2022BSE close | 38.00 | −54.4% | 108.95 | 32.10 |
| 2021BSE close | 83.30 | +91.3% | 113.60 | 43.95 |
| 2020BSE close | 43.55 | +120.5% | 60.25 | 13.95 |
| 2019BSE close | 19.75 | −40.5% | 33.75 | 12.90 |
| 2018BSE close | 33.20 | −47.2% | 87.95 | 29.50 |
| 2017BSE close | 62.90 | −3.4% | 76.50 | 46.55 |
| 2016BSE close | 65.10 | +8.5% | 78.80 | 39.50 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 27 Oct 2026 | 81.37 | 84.21 | 80.61 | 82.62 | 82.61 | 10,375 |
| 26 Oct 2026 | 80.04 | 88.04 | 79.66 | 80.20 | 81.01 | 16,631 |
| 23 Oct 2026 | 83.85 | 83.85 | 83.85 | 83.85 | 83.85 | 205 |
| 22 Oct 2026 | 86.00 | 86.00 | 85.50 | 85.56 | 85.78 | 1,611 |
| 21 Oct 2026 | 90.59 | 90.59 | 87.08 | 87.08 | 90.33 | 9,884 |
| 19 Oct 2026 | 88.85 | 88.85 | 88.85 | 88.85 | 88.85 | 2,585 |
| 16 Oct 2026 | 92.00 | 92.00 | 90.66 | 90.66 | 90.78 | 7,614 |
| 15 Oct 2026 | 92.51 | 92.51 | 91.55 | 92.51 | 91.57 | 2,217 |
| 14 Oct 2026 | 90.21 | 92.97 | 90.00 | 92.97 | 91.00 | 24,245 |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- BI
- BSE code
- 526853
- ISIN
- INE986A01012
- Industry
- Healthcare Services
- Website
- www.bilcare-group.com
- CIN
- L28939PN1987PLC043953
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1987
- Registered office
- 1028, Shiroli, Rajgurunagar, Khed, Pune 410505, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments